Structural and functional gastrointestinal abnormalities in ACTA2 R179H mice modeling multisystemic smooth muscle dysfunction syndrome
Authors:
- Ahmed A. RahmanARAhmed A. Rahman
- Rhian StavelyRSRhian Stavely
- Leah C. OttLOLeah C. Ott
- Christopher Y. HanCHChristopher Y. Han
- Kensuke OhishiKOKensuke Ohishi
- Ryo HottaRHRyo Hotta
- Alan J. BurnsABAlan J. Burns
- Sabyasachi DasSabyasachi Das
- Emily Da CruzECEmily Da Cruz
- Diana TambalaDTDiana Tambala
- Mark E. LindsayMLMark E. Lindsay
- Patricia L. MusolinoPMPatricia L. Musolino
Open Access
- 6 January 2026
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (4)
Abstract
Multisystemic smooth muscle dysfunction syndrome (MSMDS) is a rare disorder caused by ACTA2 mutations, including the R179H variant, which alters actin filament stability and dynamics and smooth muscle contractility. Cardiovascular complications dominate its clinical presentation, but gastrointestinal (GI) dysfunction significantly affects quality of life. To investigate the structural, functional, and cellular basis of gut dysmotility in MSMDS, we reviewed clinical data from 24 patients with MSMDS and studied the ACTA2 R179H mouse model. Patients exhibited severe gut dysmotility, with 75% requiring medication for chronic constipation. ACTA2 mutant mice displayed cecal and colonic dilatation, reduced intestinal length, and disrupted colonic migrating motor complexes. Delayed whole-gut transit and impaired contractile responses to electrical and pharmacological stimulation were observed. Transcriptomic analysis revealed significant actin cytoskeleton-related gene changes in smooth muscle cells, and immune profiling identified increased lymphocytic infiltration. Despite functional abnormalities, there were no obvious changes in the enteric nervous system. These findings establish ACTA2 mice as a robust model for studying GI pathology in MSMDS, elucidating the role of smooth muscle dysfunction in gut dysmotility. This model provides a foundation for developing targeted therapies aimed at restoring intestinal motility by directly addressing actin cytoskeletal disruptions in smooth muscle cells.Keywords
Funding Information
- Clinical Center (5R01NS125353)
This publication has 46 references indexed in Scilit:
- Optogenetic Activation of Cholinergic Enteric Neurons Reduces Inflammation in Experimental ColitisCellular and Molecular Gastroenterology and Hepatology, 2024
- Molecular mechanisms of cholinergic neurotransmission in visceral smooth muscles with a focus on receptor-operated TRPC4 channel and impairment of gastrointestinal motility by general anaesthetics and anxiolyticsNeuropharmacology, 2023
- Multi-disciplinary Insights from the First European Forum on Visceral Myopathy 2022 MeetingDigestive Diseases and Sciences, 2023
- Two patients with the heterozygous R189H mutation in ACTA2 and Complex congenital heart defects expands the cardiac phenotype of multisystemic smooth muscle dysfunction syndromeAmerican Journal of Medical Genetics Part A, 2017
- Rectal prolapse in Winnie mice with spontaneous chronic colitis: changes in intrinsic and extrinsic innervation of the rectumCell and tissue research, 2016
- Alterations in the distal colon innervation in Winnie mouse model of spontaneous chronic colitisCell and tissue research, 2015
- ACTA2 mutation with childhood cardiovascular, autonomic and brain anomalies and severe outcomeAmerican Journal of Medical Genetics Part A, 2013
- The actin gene family: Function follows isoformCytoskeleton, 2010
- De novo ACTA2 mutation causes a novel syndrome of multisystemic smooth muscle dysfunctionAmerican Journal of Medical Genetics Part A, 2010
- Cytokines increase proliferation of human intestinal smooth muscle cells: Possible role in inflammation-induced stricture formationInflammation, 1993